ID   BJAB/ADR
AC   CVCL_VC38
DR   cancercelllines; CVCL_VC38
DR   Wikidata; Q54797001
RX   DOI=10.3760/cma.j.issn.1009-9921.2014.03.005;
CC   Population: African; Kenyan.
CC   Virology: EBV-negative.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Groin; UBERON=UBERON_0008337.
DI   NCIt; C2912; Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_5711 ! BJAB
SX   Female
AG   5Y
CA   Cancer cell line
DT   Created: 14-05-18; Last updated: 05-10-23; Version: 9
//
RX   DOI=10.3760/cma.j.issn.1009-9921.2014.03.005;
RA   Bao S.-Q., Jiang L.-L., Zhang X.-L., Li Z.-Z., Shao X.-F., Qi H.-F.,
RA   Yang Y.-Q., Xiong D.-S.;
RT   "Establishment of multi-drug resistance human B-cell lymphoma cell
RT   line BJAB/ADR and preliminary research of its drug-resistance
RT   mechanism.";
RL   J. Leuk. Lymphoma 23:144-147(2014).
//